| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology and Institute for Clinical Neuroimmunology, Munich, Germany.
Address correspondence and reprint requests to Dr. R. Hohlfeld, Institute for Clinical Neuroimmunology, Klinikum Grosshadern, University of Munich, Marchioninistr. 15, D-81366 Munich, Germany; e-mail: rhohlfel{at}nro.med.uni-muenchen.de
Interferon beta (IFNß) reduces the relapse rate, disease activity as measured by serial MRI scanning, and disease progression of MS. Therapy with IFNß may be associated with a number of adverse reactions. Relatively frequent side effects include flu-like symptoms, transient laboratory abnormalities, menstrual disorders, and increased spasticity. Dermal injection site reactions occur after subcutaneous application of IFNß-1b and IFNß-1a. Possible side effects of IFNß include various autoimmune reactions, capillary leak syndrome, anaphylactic shock, thrombotic-thrombocytopenic purpura, insomnia, headache, alopecia, and depression. We discuss the mechanisms and management of the different side effects of IFNß.
Key words: MS—Interferon beta—Therapy—Side effects.
This article has been cited by other articles:
|
|
 |
|
  F. Poulin, P. Rico, J. Cote, and L. R. Begin Interferon Beta-Induced Panniculitis Mimicking Acute Appendicitis Arch Dermatol, August 1, 2009; 145(8): 916 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ledinek, S. Jazbec, I Drinovec, and U Rot Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report Multiple Sclerosis, July 1, 2009; 15(7): 885 - 886. [Abstract] [PDF]
|
|
|
|
|
|
G Giovannoni, O Barbarash, F Casset-Semanaz, J King, L Metz, G Pardo, J Simsarian, P. Sorensen, B Stubinski, and on behalf of the Rebif(R) New Formulation Study Gr Safety and immunogenicity of a new formulation of interferon {beta}-1a (Rebif(R) New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results Multiple Sclerosis, February 1, 2009; 15(2): 219 - 228. [Abstract] [PDF]
|
|
|
|
|
|
S Schwarz, C Knorr, H Geiger, and P Flachenecker Complementary and alternative medicine for multiple sclerosis Multiple Sclerosis, September 1, 2008; 14(8): 1113 - 1119. [Abstract] [PDF]
|
|
|
|
|
|
S Minden, D Hoaglin, S Jureidini, L Hadden, D Frankel, Y Komatsuzaki, and J Outley Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study Multiple Sclerosis, June 1, 2008; 14(5): 640 - 655. [Abstract] [PDF]
|
|
|
|
|
|
K. Cetin, K.L. Johnson, D.M. Ehde, C.M. Kuehn, D. Amtmann, and G.H. Kraft Antidepressant use in multiple sclerosis: epidemiologic study of a large community sample Multiple Sclerosis, September 1, 2007; 13(8): 1046 - 1053. [Abstract] [PDF]
|
|
|
|
 |
|
 S S O'Sullivan, E M Cronin, B J Sweeney, J F Bourke, and J Fitzgibbon Panniculitis and lipoatrophy after subcutaneous injection of interferon {beta}-1b in a patient with multiple sclerosis J. Neurol. Neurosurg. Psychiatry, December 1, 2006; 77(12): 1382 - 1383. [Full Text] [PDF]
|
|
|
|
|
|
J Porcel, J Rio, A Sanchez-Betancourt, M J Arevalo, M Tintore, N Tellez, C Borras, C Nos, and X Montalban Long-term emotional state of multiple sclerosis patients treated with interferon beta Multiple Sclerosis, November 1, 2006; 12(6): 802 - 807. [Abstract] [PDF]
|
|
|
|
|
|
L L. Mantia, D D'Amico, A Rigamonti, N Mascoli, G Bussone, and C Milanese Interferon treatment may trigger primary headaches in multiple sclerosis patients Multiple Sclerosis, August 1, 2006; 12(4): 476 - 480. [Abstract] [PDF]
|
|
|
|
|
|
M H Gottesman and S Friedman-Urevich Interferon beta-1b (Betaseron(R)/Betaferon(R)) is well tolerated at a dose of 500 mg: interferon dose escalation assessment of safety (IDEAS) Multiple Sclerosis, June 1, 2006; 12(3): 271 - 280. [Abstract] [PDF]
|
|
|
|
|
|
D Mikol, M Lopez-Bresnahan, S Taraskiewicz, P Chang, J Rangnow, and RebijectTM Study Group A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif(R)) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis Multiple Sclerosis, October 1, 2005; 11(5): 585 - 591. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Waubant and A. D. Sadovnick Interferon beta babies Neurology, September 27, 2005; 65(6): 788 - 789. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chaudhuri and P.O. Behan Treatment of multiple sclerosis: beyond the NICE guidelines QJM, May 1, 2005; 98(5): 373 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Hadjilambreva, E. Mix, A. Rolfs, J. Muller, and U. Strauss Neuromodulation by a Cytokine: Interferon-{beta} Differentially Augments Neocortical Neuronal Activity and Excitability J Neurophysiol, February 1, 2005; 93(2): 843 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Williams, A. P. Turner, M. Hatzakis Jr., J. D. Bowen, A. A. Rodriquez, and J. K. Haselkorn Prevalence and correlates of depression among veterans with multiple sclerosis Neurology, January 11, 2005; 64(1): 75 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kappos Effect of drugs in secondary disease progression in patients with multiple sclerosis Multiple Sclerosis, June 1, 2004; 10(1_suppl): S46 - S55. [Abstract] [PDF]
|
|
|
|
|
|
L. Kappos Effect of drugs in secondary disease progression in patients with multiple sclerosis Multiple Sclerosis, May 1, 2004; 10(3_suppl): S46 - S55. [Abstract] [PDF]
|
|
|
|
|
|
S. Schmidt, T. Schneider, I. Schmidt-Wolf, Y. Ko, U. Schlegel, T. Klockgether, and H.-J. Hertfelder Letter to the editor Multiple Sclerosis, April 1, 2004; 10(2): 243 - 244. [PDF]
|
|
|
|
|
|
H. L. Tremlett and J. Oger Interrupted therapy: Stopping and switching of the {beta}-interferons prescribed for MS Neurology, August 26, 2003; 61(4): 551 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Casoni, E. Merelli, R. Bedin, A. Martella, A. Cesinaro, and A. Bertolotto Necrotizing skin lesions and NA Bs development in a multiple sclerosis patient treated with IFN{beta} 1b Multiple Sclerosis, August 1, 2003; 9(4): 420 - 423. [Abstract] [PDF]
|
|
|
|
|
|
H. Zephir, J. De Seze, T. Stojkovic, B. Delisse, D. Ferriby, M. Cabaret, and P. Vermersch Multiple sclerosis and depression: influence of interferon b therapy Multiple Sclerosis, June 1, 2003; 9(3): 284 - 288. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Pasic, W. C. Levy, and M. D. Sullivan Cytokines in Depression and Heart Failure Psychosom Med, March 1, 2003; 65(2): 181 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tanvetyanon, E. A Stadtmauer, and L. A Kerson Concurrent Administration of Interferon Alfa-2b and Beta-1a Ann. Pharmacother., January 1, 2003; 37(1): 77 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Altintas, Y Alici, M Melikoglu, and A Siva Arthritis during interferon beta-1b treatment in multiple sclerosis Multiple Sclerosis, December 1, 2002; 8(6): 534 - 536. [Abstract] [PDF]
|
|
|
|
 |
|
 J. S. Burks, B. G. Arnason, P. K. Coyle, C. C. Ford, A. Noronha, and K. W. Rammohan Issues and Practices in Multiple Sclerosis Neurorehabil Neural Repair, December 1, 2002; 16(4): 307 - 320. [Abstract] [PDF]
|
|
|
|
|
|
J. Reess, J. Haas, K. Gabriel, A. Fuhlrott, and M. Fiola Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-la (AVONEX(R)) therapy Multiple Sclerosis, September 1, 2002; 8(1_suppl): 15 - 18. [Abstract] [PDF]
|
|
|
|
|
|
P. A. Calabresi Considerations in the treatment of relapsing-remitting multiple sclerosis Neurology, April 23, 2002; 58(90084): S10 - 22. [Abstract] [Full Text]
|
|
|
|
|
|
J Reess, J Haas, K Gabriel, A Fuhlrott, and M Fiola Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX(R)) therapy Multiple Sclerosis, February 1, 2002; 8(1): 15 - 18. [Abstract] [PDF]
|
|
|
|
|
|
E. M. Yoshida, S. L. Rasmussen, U. P. Steinbrecher, S. R. Erb, C. H. Scudamore, S. W. Chung, J. J. Oger, and S. A. Hashimoto Fulminant liver failure during interferon beta treatment of multiple sclerosis Neurology, May 22, 2001; 56(10): 1416 - 1416. [Full Text] [PDF]
|
|
|
|
|
|
D. L. Brown, I. S. Login, L. Borish, and P. L. Powers An urticarial IgE-mediated reaction to interferon {beta}-1b Neurology, May 22, 2001; 56(10): 1416 - 1417. [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Chen, A. Rivera, N. Ron, J. P. Dougherty, and Y. Ron A gene therapy approach for treating T-cell-mediated autoimmune diseases Blood, February 15, 2001; 97(4): 886 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Von Raison, H. Abboud, C. S. Val, P. Brugieres, and P. Cesaro Acute demyelinating disease after interferon {beta}-1a treatment for multiple sclerosis Neurology, November 14, 2000; 55(9): 1416 - 1417. [Full Text] [PDF]
|
|
|
|
|
|
A. Feinstein Multiple sclerosis, disease modifying treatments and depression: a critical methodological review Multiple Sclerosis, October 1, 2000; 6(5): 343 - 348. [Abstract] [PDF]
|
|
|
|
|
|
K Gottberg, A Gardulf, and S Fredrikson Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects Multiple Sclerosis, October 1, 2000; 6(5): 349 - 354. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
